Public advisory

Archive – Health Canada Clarification on Status of Evra Contraceptive Skin Patch in Canada

Starting date:
November 28, 2005
Posting date:
November 28, 2005
Type of communication:
Advisory
Subcategory:
Drugs
Source of recall:
Health Canada
Issue:
Labelling and Packaging
Audience:
General Public
Identification number:
RA-11000445

Health Canada is advising consumers that it is currently reviewing whether any product labelling changes are required for the Canadian version of the Ortho Evra contraceptive skin patch. It is important to note that the dosages and the manufacturing processes for the Canadian version are different than the patch approved in the United States.

Health Canada is taking this action in light of recent changes in the United States to product labelling information for the Evra patch.

Health Canada continues to monitor the safety of Evra through its post-marketing surveillance program. Once the review of the data is complete, Health Canada will quickly communicate any new safety information on this product to health care professionals and consumers, so they can make timely decisions on the risks and benefits.

On November 10, 2005, the U.S. Food and Drug Administration approved revised labelling for the Ortho Evra contraceptive skin patch that includes a new, bolded warning alerting health care providers that the amount of estrogen delivered through the skin produces a higher estrogen exposure than when taking the typical birth control pill. Greater exposure to estrogen may increase the risk of blood clots. The full Food and Drug Administration advisory is located at: FDA Updates Labeling for Ortho Evra Contraceptive Patch

The current Canadian labelling information on Evra contains a description of the risks and proper use of the product. There is also a detailed section on the importance of discontinuing the medication at the earliest sign of blood clots. Common symptoms for blood clots can include, but are not limited to, pain in the calf, shortness of breath, chest pain or coughing blood.

As with any medication, patients concerned about the risks and benefits of Evra should speak to their physician.

Archive - Health Canada update on status of Evra contraceptive skin patch in Canada

2006-03-30 | Health products

Advisory

Media enquiries

Health Canada
613-957-2983

Public enquiries

613-957-2991
1-866-225-0709